Unilink Pharma Private Limited

Unilink Pharma Private Limited, established on February 23, 2005, is a privately held pharmaceutical company headquartered in Chennai, Tamil Nadu, India. The company is registered under the Corporate Identification Number (CIN) U24232TN2005PTC055459. Its authorized capital stands at ₹3.00 crore, with a paid-up capital of ₹1.60 crore. The registered office is located at New No.111, Old No.23 Parthasarathypuram, T Nagar, Chennai-600017, Tamil Nadu, India.

The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Over the years, Unilink Pharma has expanded its product portfolio to cover 80% of the therapeutic segment, employing a multi-pronged marketing approach that includes creating stock points outside India, global tendering, and offering tailor-made products to buyers with regulatory support.

Unilink Pharma operates a 30,000-square-foot manufacturing facility in Chennai, Tamil Nadu. This state-of-the-art plant is equipped to produce a wide range of pharmaceutical products, including tablets, capsules, syrups, and injections. The facility adheres to current Good Manufacturing Practices (cGMP) and holds ISO 9001 certifications, ensuring high-quality production standards.

The leadership team at Unilink Pharma comprises:

• Karunakaran Vijaya: Managing Director, appointed on February 23, 2005.

• Sreenivasan Karunakaran: Whole-Time Director, appointed on October 2, 2009.

These leaders bring extensive experience in pharmaceutical manufacturing and export, driving the company's growth and strategic direction.

Unilink Pharma has made significant strides in obtaining regulatory approvals for its products in various international markets. The company's manufacturing facility is WHO-certified, indicating compliance with international standards for pharmaceutical manufacturing. Additionally, the facility holds cGMP and ISO 9001 certifications, further demonstrating its commitment to quality. While specific details regarding approvals from the US FDA, EMA, MHRA, and TGA are not publicly disclosed, the company's adherence to international standards suggests a proactive approach to meeting regulatory requirements in these regions.

Unilink Pharma has strategically positioned itself to penetrate emerging markets in Africa, Latin America, and Southeast Asia. The company's WHO-certified manufacturing facility enhances its credibility and facilitates access to these regions. By offering a diverse product portfolio and ensuring compliance with international standards, Unilink Pharma aims to address the healthcare needs of these growing markets.

Unilink Pharma's geographic strategy focuses on diversification to mitigate concentration risk. The company exports products to various countries, as indicated by its total export value of $3.9 million USD across 79 shipments. This approach not only spreads risk but also leverages opportunities in multiple markets. The strategic direction emphasizes expanding the product portfolio and enhancing market presence through regulatory compliance and quality assurance.

Specific details regarding Unilink Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's adherence to international standards, including WHO certification and cGMP compliance, suggests a commitment to meeting FDA requirements for potential market entry.

Unilink Pharma's manufacturing facility is WHO-certified, indicating compliance with international standards for pharmaceutical manufacturing. Additionally, the facility holds cGMP and ISO 9001 certifications, reflecting its commitment to quality. While specific details regarding EU GMP certificates and EDQM status are not publicly disclosed, the company's adherence to international standards suggests a proactive approach to meeting EU regulatory requirements.

Unilink Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian pharmaceutical regulations. The company's adherence to cGMP and ISO 9001 standards further demonstrates its commitment to quality and regulatory compliance. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly available.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Unilink Pharma. The company's adherence to international standards, including WHO certification and cGMP compliance, suggests a proactive approach to regulatory compliance.

Unilink Pharma operates in a competitive landscape with several key players in the pharmaceutical manufacturing and export sector. While specific competitors are not identified in the available data, the company's focus on quality, regulatory compliance, and a diverse product portfolio positions it favorably in the market. The company's export value of $3.9 million USD across 79 shipments indicates a growing presence in the global market.

Unilink Pharma's key differentiators include:

• Quality Assurance: The company's manufacturing facility is WHO-certified and adheres to cGMP and ISO 9001 standards, ensuring high-quality products.

• Diverse Product Portfolio: Unilink Pharma offers a range of pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic categories.

• Global Reach: The company's export value of $3.9 million USD across 79 shipments reflects its expanding global presence.

Unilink Pharma's current strategic direction focuses on expanding its product portfolio and enhancing market presence through regulatory compliance and quality assurance. The company's adherence to international standards, including WHO certification and cGMP compliance, positions it well for future growth in both existing and emerging markets.

Unilink Pharma has demonstrated a consistent track record in pharmaceutical manufacturing and export, with a total export value of $3.9 million USD across 79 shipments. The company's adherence to international standards, including WHO certification and cGMP compliance, indicates reliability and commitment to quality. While specific details regarding export volume consistency and reliability indicators are not publicly available, the company's strategic focus on quality and regulatory compliance suggests a strong foundation for sustained performance.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• WHO Certification: Indicates compliance with international standards for pharmaceutical manufacturing.

• cGMP Certification: Demonstrates adherence to current Good Manufacturing Practices.

• ISO 9001 Certification: Reflects a commitment to quality management systems.

These certifications can typically be verified through the company's official website or by contacting the company directly.

When considering Unilink Pharma as a supplier, importers should:

• Verify Certifications: Ensure the company holds valid WHO, cGMP, and ISO 9001 certifications.

• Assess Financial Stability: Review the company's financial statements to evaluate financial health.

• Evaluate Product Quality: Request product samples and conduct quality assessments.

• Check Regulatory Compliance: Confirm the company's compliance with relevant regulatory bodies.

• Review Export History: Analyze the company's export records for consistency and reliability.

Red flags to watch for include expired certifications, irregular financial statements, and unresolved regulatory issues. Recommended pre-order checks involve verifying the company's certifications, assessing financial stability, and evaluating product quality through samples.